FATE THERAPEUTICS INC Payments of Debt Issuance Costs
FATE THERAPEUTICS INC (FATE) reported Payments of Debt Issuance Costs of $10.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-02.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2020-03-02
- FATE THERAPEUTICS INC payments of debt issuance costs for the quarter ending 2017-12-31 was $0.00.
- FATE THERAPEUTICS INC payments of debt issuance costs for the quarter ending 2014-12-31 was $0.00.
- FATE THERAPEUTICS INC payments of debt issuance costs for fiscal 2017 was $10.00K.
- FATE THERAPEUTICS INC payments of debt issuance costs for fiscal 2014 was $26.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $10.00K 10-K · filed 2020-03-02 | |
| 2017-09-30 | $10.00K 10-Q · filed 2018-11-01 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $26.00K 10-K · filed 2017-03-16 | |
| 2014-09-30 | $26.00K 10-Q · filed 2015-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |